Synthesis and biological evaluation of $^{125}$I/$^{123}$I-labelled analogues of citalopram and escitalopram as potential radioligands for imaging of the serotonin transporter

Jacob Madsen,a* Betina Elfving,b† Vibe G. Frokjaer,b Birgitte R. Kornum,b Gerda Thomsen,b Lars Martiny,c and Gitte M. Knudsenb

Two novel radioligands for the serotonin transporter (SERT), $^{[125]I}$-[3-[5-iodo-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl]-propyl]-dimethylamine ([$^{125}$I]-2) and $^{[125]I}$-[3-[5-iodo-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl]-propyl]-dimethylamine ([$^{125}$I]-S-2) were synthesized in a Br/$^{125}$I exchange reaction. Binding experiments in rats yielded $K_d$ values of 0.7 ± 0.06 and 0.52 ± 0.02 nM for [$^{125}$I]-2 and [$^{125}$I]-S-2, respectively. One hour after intravenous injection of [$^{125}$I]-2, 0.34% of the injected dose had accumulated in the brain. The highest hypothalamus-to-cerebellum ratio was reached 2 h after injection of [$^{125}$I]-S-2 and amounted to 2.4. Pre-treatment experiments with paroxetine resulted in effective reduction of the target-to-cerebellum ratios.

The corresponding iodine-123 labelled compound $^{[123]I}$-[3-[5-iodo-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl]-propyl]-dimethylamine [$^{123}$I]-S-2 was investigated in a pig single photon emission computed tomography (SPECT) study. Between 60 and 110 min after IV injection, the midbrain-to-cerebellum ratio was 1.2. However, the uptake did not differ between high-density and medium-density regions questioning the feasibility of the radioligand in imaging cortical SERT distribution in vivo.

These data suggest that the iodine-labelled derivatives of citalopram and escitalopram are not superior to another SPECT tracer for the SERT, namely [$^{123}$I]ADAM.

Keywords: serotonin transporter; escitalopram; SPECT; iodine labelling

Introduction

Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are non-invasive techniques, which can be applied for in vivo investigations of biological processes in humans using appropriate radioligands.1 Radio-ligands are labelled with radionuclides such as $^{11}$C ($t_{1/2} = 20.4$ min) or $^{18}$F ($t_{1/2} = 109$ min) for PET and $^{99m}$Tc ($t_{1/2} = 6.0$ h) or $^{123}$I ($t_{1/2} = 13.1$ h) for SPECT. The advantages of SPECT are first of all lower costs and the more facile handling of often longer lived SPECT radioligands, whereas PET is a quantitative method and the use of radioligands labelled with short-lived isotopes allow multiple investigations in the same subject on the same day.

The serotonin transporter (SERT) is believed to play a central role in mental disorders arising from disturbances in the serotonin system.2 There are now several PET-radioligands available for imaging of the SERT in the living human brain, especially the diarylsulfides $^{[11]}$C[DA8B,3,4 $^{[11]}$C[MADAM,5,6 and more recently $^{[11]}$C[HOMADAM.7,8 For SPECT imaging, iodinated diarylsulfides such as $^{[123]}$I[ODAM, $^{[123]}$I[DOM and $^{[123]}$I[ADAM have all been suggested as candidates for visualization of the SERT in vivo.9–11 Within this series of compounds, $^{[123]}$I[ADAM is the most promising candidate as a SPECT radioligand and has been evaluated in humans.12–14 So far, $^{[123]}$I[ADAM remains the only available SPECT radioligand for human studies. However, robust quantification of cerebral SERT requires a 120-min data acquisition and another potential disadvantage with this radioligand is the presence of a lipophilic metabolite seen in some subjects.14

In this paper, we report the radiolabelling and initial biological studies of iodinated derivatives of the selective serotonin reuptake inhibitors (SSRIs), citalopram and escitalopram. The novel radioligands $^{[125]}$I-[3-[5-iodo-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl]-propyl]-dimethylamine ([$^{125}$I]-2) and
Materials and methods

No-carrier-added $[^{125}]$I-sodium iodide solution (2 Ci/μmol) was purchased from Amersham Biosciences. Paroxetine hydrochloride was purchased from Smith-Kline Beecham, West Sussex UK. Male Sprague-Dawley rats weighing 206–396 g were used for the biological studies (M&B, Denmark). HPLC was performed on a Merck Hitachi fitted with in-line radio detection. Log P values were calculated with QikProp. $[3\text{-}[5\text{-bromo-1-}(4\text{-fluorophenyl})\text{-1,3-dihydroisobenzofuran-1-yl}]\text{-propyl}]\text{-dimethylamine}$ (1), $[3\text{-}[5\text{-bromo-1-}(4\text{-fluorophenyl})\text{-1,3-dihydroisobenzofuran-1-yl}]\text{-propyl}]\text{-dimethylamine}$ (1), $[3\text{-}[5\text{-bromo-1-}(4\text{-fluorophenyl})\text{-1,3-dihydroisobenzofuran-1-yl}]\text{-propyl}]\text{-dimethylamine}$ (2) and $[3\text{-}[5\text{-iodo-1-}(4\text{-fluorophenyl})\text{-1,3-dihydroisobenzofuran-1-yl}]\text{-propyl}]\text{-dimethylamine}$ (2) were gifts from H. Lundbeck A/S, Copenhagen, Denmark. $[^{125}]$-S-2 was prepared by MAP Medical, Finland, from the stannylated precursor, $[3\text{-}[4\text{-fluorophenyl})\text{-5-trIBUTYlstannyl-1,3-dihydroisobenzofuran-1-yl}]\text{-propyl}]\text{-dimethylamine}$.15

**Radiosynthesis of $[^{125}]$-2 and $[^{125}]$-S-2**

To a 1-ml vial charged with 1 (1.6 mg, 4.2 μmol), citric acid (5.3 mg, 27.6 μmol), 2,5-dihydroxybenzoic acid (3.9 mg, 25.3 μmol), isoascorbic acid (3.6 mg, 20.4 μmol) and CuSO4 (0.2 ml, 1 mg/ml) was added acidic acid (0.2 ml, 1 M) and $[^{125}]$iodide (5 mCi). The vial was sealed and heated to 140 °C for 2 h. After cooling to room temperature, the mixture was loaded on a Seppak Plus C$_{18}$ cartridge (Waters). The cartridge was flushed with H$_2$O (2 ml) and the radioactive material was eluted with 70% CH$_2$CN (2 ml). The eluted material was evaporated to approximately 300 μl and diluted with 200 μl HPLC eluent. The mixture was split into two portions before purification. HPLC purification was performed on an analytical column (RP, OdDMeSi, 5 μm, 120 Å, 4.6 x 250 mm). HPLC eluent A: 0.1% TFA/10% CH$_2$CH and B: 0.1% TFA/90% CH$_3$CN were used. From 0–40 min, the eluent B was linearly increased from 25 to 40% with a 1-ml/min flow rate. The purified product, $[^{125}]$-2, was analysed on a second HPLC system using an analytical column as above. The solvents A: 0.1% TFA/10% CH$_2$CH and B: 0.1% TFA/90% CH$_3$CN were used. From 0–30 min, solvent B was increased from 40 to 60%.

Applying the above procedure $[^{125}]$-S-2 was prepared using S-1 as the starting material.

**In vitro binding studies**

Saturation binding studies were performed with rat brain homogenates of cerebrum ($n=3$) according to a previous published procedure$^{16}$ and the $K_d$ values were determined at 37 °C.$^{17}$

**Ex vivo binding studies**

Three rats per time point were used for ex vivo brain distribution studies. All animal experiments were carried out in accordance with the European Communities Council Resolves of 24th November 1986 (86/609/ECC) and approved by the Danish Animal Research Inspectorate (Journal number 2003/561–745).

$[^{125}]$-S-2 was injected in the tail vein and the rats were decapitated 1, 2, 3, 4 and 6 h later. Rats injected with $[^{125}]$-S-2 were decapitated after 2 h. In all cases, the brains were quickly removed and dissected on an ice-cold tile. Eight brain regions (olfactory tubercles, hypothalamus, cerebellum, hippocampus, corpus striatum, thalamus, pre-frontal cortex and remaining cortex) were dissected, weighted and the accumulated radioactivity was counted. Paroxetine (3 mg/kg) was used in competitive binding studies. The region of interest (ROI)-to-cerebellum ratios were determined as [(ROI(cpsm)/ROI(g)/(cerebellum(cpsm)/cerebellum(g))). The percent dose per gram brain tissue (% dose/g) was calculated as [(ROI(cpsm)/g ROI tissue)/total injected dose] for each brain region.
uniform attenuation correction with an attenuation coefficient of 0.10 cm⁻¹. The complete subtraction and reconstruction algorithm was carried out in Matlab 6.5. The resulting series of images were converted into a dynamic file and a summed image using all frames.

For calculating time-activity curves (TACs) from midbrain, frontal cortex and cerebellum, the summed image was co-registered to a pig brain MRI-based atlas using the program Register, a tri-planer viewer developed at the Montreal Neurological Institute, McGill University, Canada. Registration was achieved by manually marking homologue anatomical positions in the two scans and minimizing the root mean square distance between the landmarks. Then, TACs from the ROIs were calculated as previously described. To minimize statistical noise in the signal, the regions thalamus, diencephalon and mesencephalon were pooled to obtain a larger midbrain region.

Results
Radiochemistry
The radiosyntheses of [125I]-2 and [125I]-S-2 were performed in a one step reaction from the corresponding bromo precursors 1 and S-1, respectively (Scheme 1).

For each radioligand, the radioactive product was collected after 29.5–30.5 min in two separate HPLC runs. The bromo precursors 1 and S-1 were eluted after 20.5–26 min. The iodo derivatives [125I]-2 and [125I]-S-2, were obtained in approximately 35% radiochemical yield. The radiochemical purity of the final product was >98% as determined by analytical HPLC and no precursor could be detected in the UV trace of the HPLC chromatogram. The identity of the product was confirmed by co-elution with the reference substance 2 in each case. The purified product was evaporated and formulated in 50% EtOH. In this medium, [125I]-2 has proven to be stable for at least 2 months (> 95% pure).

Log P value
The iodo derivative 2 has a calculated log P value of 5.2.

In vitro binding studies
From saturation experiments in rat membrane homogenates previously described in detail, Scatchard plot analysis was performed. The Scatchard plot was linear indicating only one binding site and the Kd values (mean ± SEM) were 0.7 ± 0.06 nM and 0.52 ± 0.02 nM for the iodinated derivatives [125I]-2 and [125I]-S-2, respectively.

Ex vivo brain distribution studies in rats
Between 1.25 and 1.95 MBq of [125I]-2 or [125I]-S-2 was intravenously injected in the tail vein of the rats. Rats receiving [125I]-2 were decapitated between 1 and 6 h after injection as indicated in Table 1. The radioligand penetrated the blood–brain barrier resulting in a brain uptake of 0.34% injected dose after 1 h. After decapitation, the brain regions of interest were

<table>
<thead>
<tr>
<th>Brain region</th>
<th>1 h (n = 3)</th>
<th>2 h (n = 3)</th>
<th>3 h (n = 3)</th>
<th>4 h (n = 3)</th>
<th>6 h (n = 2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olfactory tuberli</td>
<td>0.18 ± 0.03</td>
<td>0.09 ± 0.02</td>
<td>0.08 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>0.03 ± 0.00</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td>0.23 ± 0.03</td>
<td>0.12 ± 0.02</td>
<td>0.11 ± 0.02</td>
<td>0.05 ± 0.02</td>
<td>0.03 ± 0.00</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>0.18 ± 0.03</td>
<td>0.08 ± 0.01</td>
<td>0.07 ± 0.01</td>
<td>0.03 ± 0.01</td>
<td>0.03 ± 0.00</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>0.23 ± 0.04</td>
<td>0.12 ± 0.02</td>
<td>0.11 ± 0.20</td>
<td>0.04 ± 0.01</td>
<td>0.03 ± 0.01</td>
</tr>
<tr>
<td>Corpus striatum</td>
<td>0.23 ± 0.05</td>
<td>0.11 ± 0.02</td>
<td>0.09 ± 0.02</td>
<td>0.04 ± 0.01</td>
<td>0.03 ± 0.01</td>
</tr>
<tr>
<td>Thalamus</td>
<td>0.28 ± 0.04</td>
<td>0.17 ± 0.04</td>
<td>0.12 ± 0.02</td>
<td>0.05 ± 0.01</td>
<td>0.04 ± 0.01</td>
</tr>
<tr>
<td>Pre-frontal cortex</td>
<td>0.24 ± 0.04</td>
<td>0.11 ± 0.02</td>
<td>0.09 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>0.03 ± 0.00</td>
</tr>
<tr>
<td>Remaining cortex</td>
<td>0.23 ± 0.04</td>
<td>0.10 ± 0.02</td>
<td>0.09 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>0.03 ± 0.00</td>
</tr>
</tbody>
</table>

Values are mean ± SD.

Scheme 1. Radiosynthesis of [125I]-2 and [125I]-S-2.
dissected and weighted, and the radioactive content was counted and regional brain distributions (% dose/g) of compound \([125^I]}-2\) was determined (Table 1).

The maximal target-to-cerebellum ratios were found in the thalamus and hypothalamus regions after 2 h. Rats receiving \([125^I]}-(S)-2\) were decapitated after 2 h and the hypothalamus- and thalamus-to-cerebellum ratios were 2.1 and 2.4, respectively. In the blocking experiments, paroxetine (3 mg/kg) was injected in the tail vein of the rats \((n = 3)\) 10 min prior to injection of \([125^I]}-2\). After 2 h, the rats were decapitated and the thalamus- and hypothalamus-to-cerebellum ratios were significantly reduced (Figure 1).

**SPECT study**

\([123^I]}-(S)-2\) was studied *in vivo* in the pig brain. Summed images and TACs from the midbrain, frontal cortex and cerebellum are shown in Figure 2. In this set-up, \([123^I]}-(S)-2\) peaks at around 20–40 min after injection. Uptake is highest in midbrain, slightly lower in frontal cortex and lowest in cerebellum. Target-to cerebellar area under the curve (AUC) ratio is 1.20 for midbrain and 1.13 for frontal cortex.

**Discussion**

In our search for new SPECT tracers to study the SERT *in vivo*, we have synthesized the novel iodinated radioligands \([125^I]}-2\) and \([125^I]}-(S)-2\), which are structurally related to the SSRI’s citalopram and escitalopram. The iodo derivative 2 has a calculated log \(P\) of 5.2 and displays high affinity for the SERT and is highly selective as compared with the dopamine and noradrenaline transporter (Table 2).

**Table 2.** Inhibition of \([^3H]}-5\text{-HT}, [^3H]}\text{-DA and [^3H]}\text{-NA uptake for citalopram and iodo derivative 2}\)

<table>
<thead>
<tr>
<th>Compound</th>
<th>R</th>
<th>5-HT IC50 (nM)</th>
<th>DA IC50 (nM)</th>
<th>NA IC50 (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citalopram</td>
<td>CN</td>
<td>1.8</td>
<td>40 000</td>
<td>6100</td>
</tr>
<tr>
<td>2</td>
<td>I</td>
<td>3.5</td>
<td>2600</td>
<td>1300</td>
</tr>
</tbody>
</table>

![Figure 1](image1.png)

**Figure 1.** Thalamus- and hypothalamus-to-cerebellum ratios of \([125^I]}-2\) and \([125^I]}-(S)-2\) at different time points after intravenous injection. In the blocking experiments, the rats were sacrificed 2 h after injection. The values are mean ± SD.

![Figure 2](image2.png)

**Figure 2.** Summed SPECT images and TACs from the midbrain, frontal cortex and cerebellum of \([123^I]}-(S)-2\).
The radioiodinated products, [125I]-2 or [125I]-(S)-2, were well separated from the bromo precursors 1 or S-1, respectively, under the HPLC conditions applied. The $K_d$ values of [125I]-2 (0.70 ± 0.06 nM) and [125I]-(S)-2 (0.52 ± 0.02 nM) are comparable with the values obtained for [3H]citalopram ($K_d$ = 1 nM) and [3H]escitalopram ($K_d$ = 0.71 nM).16 In ex vivo rat studies, [125I]-2 penetrated the blood–brain barrier (0.34% injected dose 1 h after injection) and the highest target-to-cerebellum ratios at all time points were found in the thalamus and hypothalamus. This corresponds well with the known high SERT densities in these regions of the brain.23 Cerebellum, which has a low density of SERT sites, was used as reference region.23 A maximal thalamus-to-cerebellum ratio of 1.9 was observed 2 h after intravenous injection of [125I]-2. After pre-treatment with the SSRI paroxetine, the major radiometabolites of [125I]-2 were changed to a methyl group ($K_d$ = 1 nM)22 and [125I]escitalopram, displayed higher affinity for monkey SERT compared with rat SERT.32

Compared with [125I]-2 injection of [125I]-(S)-2 resulted, as expected, in an increased target-to-background ratio in ex vivo rat studies. The hypothalamus- and thalamus-to-cerebellum ratios were increased from 1.6 and 1.9 to 2.1 and 2.4, respectively (Figure 1).

The maximal uptake was reached after 1 h. The maximal target-to-cerebellum ratio reached after 2 h (Figure 3) was relatively fast compared with [125I]ADAM,4 which peaks after 4 h and slightly slower than [125I]IDAM,29 which peaks already after 60 min.

The target-to-cerebellum ratio was somewhat lower than $[125I]JADAM$ and $[125I]IDAM$, where hypothalamus-to-cerebellum ratios are 5.0 and 2.8, respectively.26 TACs show that in the pig brain the uptake of [125I]-2 peaks at around 20–40 min after injection, slightly faster in transporter rich than in transporter poor regions. Uptake was higher in transporter rich regions as midbrain compared with cerebellum with very low densities of SERT. Target-to-cerebellar AUC ratio was 1.20 for the high-binding region midbrain. The TAC from the frontal cortex and the midbrain are almost overlapping, although a difference in SERT concentrations between the two regions is approximately 3.5, as measured with [11C]DASB PET.27 This can partly be ascribed to partial volume effects that are caused by the limited spatial resolution of SPECT. This leads to an underestimation of regional radioactivity distribution in regions with high radioactivity concentration relative to the surroundings, and also to the converse situation with overestimation in regions with low radioactivity concentration.29 With a co-registered magnetic resonance image, it is possible to correct for these effects of partial volume.25 Even when partial volume effects and the small volume of the pig brain (180 g) are taken into account, the TAC in the pig brain is considerably less promising than in our rat data. However, without a partial volume correction, we still detect a difference between high and low activity regions, and this difference is expected to be even higher in partial volume corrected data.

The low target-to-background ratio in the brain could either be due to too high non-specific binding or to too low specific binding. The estimated log $P$ value of 5.2, which is considered to be relatively high, could result in slow washout of non-specific binding. We previously found that the non-specific binding of the carbon-11 labelled $S$-enantiomer of citalopram ($log P$ 3.6) is also high in rats,30,31 as it is in humans,30 and as well when a carbon-11 labelled citalopram derivative where the cyano group was changed to a methyl group ($log P$ 4.6) was studied in non-human primates.32

It is also possible that the binding affinity of [125I]-(S)-2 (0.52 ± 0.02 nM) for SERT is too low. We have previously estimated that the imaging of SERT in a high-density region in the human brain requires radioligands with $K_d$ values between 0.03 and 0.3 nM.17 We do not know whether the binding affinity of [125I]-(S)-2 displays species differences in the rat and human brain. However, based on our previous experiments that included radiolabelled (+)- McN5652, DASB, ADAM, MADAM, escitalopram, fluoxetine and paroxetine, only paroxetine displayed higher affinity for monkey SERT compared with rat SERT.17 If [125I]-(S)-2 also has lower or equal affinity for the human SERT compared with the rat SERT, our finding supports the notion that successful SERT radioligands should have an affinity in the range given above.

Metabolic degradation of citalopram invariably occurs at the dimethyl amino group.33 Assuming that the minor differences between the cyano- and iodo substituents present in citalopram and 2 do not play a role for the metabolic process, the two major radiometabolites of [125I]-(S)-2 would be either glucoronides or the desmethyl derivative. This is in accordance with our experience with $S$-[N-methyl-11C]citalopram in non-human primates where we found indications of formation of polar metabolites only (unpublished data). Therefore, we do not expect the formation of lipophilic radiolabelled metabolites from [125I]-(S)-2. Although glucuronides cannot cross the blood–brain barrier, we cannot exclude that a radiolabelled demethylated metabolite to some extent may also contribute to the insufficient target-to-background signal in pigs.

Conclusions

Our results indicate that despite its superior selectivity towards the SERT, [125I]-(S)-2 is not better SPECT radioligand than...
[123]IADAM for SERT. It is difficult to predict the in vivo characteristics of a radioligand based on in vitro data alone. Studies in small animals such as rats can give good indications of the fate of the radioligand. However, for a series of radioligands with promising properties a conclusion should be based on an in vivo PET/SPECT study in larger animals such as non-human primates or pigs. Based on our data, [123I]-{(5)-2 does not show a great potential as a SERT-radioligand for human SPECT studies.

Acknowledgements

This work is supported by The Centre for Drug Design and Transport through a grant from The Danish Medical Research Council. Anne Mette Dall and Inge Møller are gratefully acknowledged for excellent technical assistance.

References